MedPath

Ocuphire Pharma

Ocuphire Pharma logo
🇺🇸United States
Ownership
Public
Established
2018-02-01
Employees
14
Market Cap
$31.9M
Website
http://www.ocuphire.com
Introduction

Ocuphire Pharma, Inc. engages in the research and development of ophthalmic biopharmaceutical products. It focuses on developing and commercializing therapies for the treatment of several eye disorders. The company was founded by Mina Patel Soouch and Alan R. Meyer in February 2018 and is headquartered in Farmington Hills, MI.

Ocuphire Pharma releases results from MIRA-2 and MIRA-3 clinical trials for phentolamine

Ocuphire Pharma announced results from 2 Phase 3 trials (MIRA-2 and MIRA-3) showing phentolamine ophthalmic solution 0.75% (Ryzumvi) effectively reversed pharmacologically-induced mydriasis with a favorable safety profile. Published in *Ophthalmology*, the trials demonstrated a statistically significant reversal at 90 minutes compared to placebo, with rapid onset and significant improvements in pupil diameter up to 24 hours. The solution, approved by the FDA, is marketed for treating mydriasis caused by adrenergic agonists or parasympatholytic agents.
globenewswire.com
·

Ocuphire Pharma Announces Publication of Full Phase 3

Ocuphire Pharma announced the publication of Phase 3 trial results for RYZUMVI™ (Phentolamine Ophthalmic Solution 0.75%) in Ophthalmology, demonstrating its efficacy and safety in reversing pharmacologically-induced mydriasis.
optometrytimes.com
·

What happened in optometry this week: September 2 - September 6

BVI to launch SERENITY and SERENITY Toric IOLs in 2025; modeling life after blue zones for longevity; hyperopia linked to depression risk; saline-powered ultra-thin battery for smart contact lenses; Ocuphire Pharma starts phase 3 VEGA-3 trial for presbyopia treatment.
healio.com
·

First subjects dosed in phase 3 trial of phentolamine ophthalmic solution for presbyopia

Ocuphire Pharma has initiated the VEGA-3 phase 3 trial, evaluating phentolamine ophthalmic solution 0.75% for presbyopia in 545 participants. The trial aims to assess efficacy and safety as a noninvasive alternative to traditional measures, with topline data expected in 2025.

Ocuphire Pharma doses first patient in phase 3 VEGA-3 clinical trial

Ocuphire Pharma has initiated the VEGA-3 phase 3 trial of phentolamine ophthalmic solution 0.75% for presbyopia treatment, aiming for a non-invasive, convenient alternative. The trial follows positive results from the VEGA-2 study, which demonstrated rapid onset, favorable safety profile, and sustained effect. VEGA-3 will evaluate 545 participants with presbyopia, with top-line data expected in 2025, potentially supporting a supplemental New Drug Application.
globenewswire.com
·

UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial

Ocuphire Pharma's VEGA-3 Phase 3 trial for Phentolamine Ophthalmic Solution 0.75% in presbyopia has dosed its first participants, with top-line data expected in H1 2025. The LYNX-2 Phase 3 trial for visual acuity issues post-keratorefractive surgery is ongoing, with top-line data anticipated in Q1 2025.
finance.yahoo.com
·

UPDATE – Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine

Ocuphire Pharma initiates VEGA-3 Phase 3 trial for Phentolamine Ophthalmic Solution 0.75% to treat presbyopia, with top-line data expected in H1 2025. The company also anticipates LYNX-2 Phase 3 trial data for visual acuity issues post-keratorefractive surgery in Q1 2025.
optometrytimes.com
·

Ocuphire Pharma announces dosing of first patient in phase 3 VEGA-3 clinical trial

Ocuphire Pharma has dosed the first patient in its VEGA-3 phase 3 trial of phentolamine ophthalmic solution 0.75% for presbyopia treatment, aiming for a non-invasive alternative. The VEGA-3 trial is randomized, double-masked, placebo-controlled, and multi-center, evaluating the solution in 545 participants. Top-line data is expected in 2025.
finance.yahoo.com
·

12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds

The article highlights 12 undervalued biotech stocks favored by hedge funds, focusing on companies like MEI Pharma, Ocuphire Pharma, and Voyager Therapeutics. It discusses the biotech industry's growth, driven by innovation, M&A activity, and FDA approvals, with a positive outlook for 2024 despite challenges like drug pricing and regulatory scrutiny.
© Copyright 2025. All Rights Reserved by MedPath